Lovastatin nanoparticle synthesis and characterization for better drug delivery

Open Biotechnology Journal

Volumn 5, Issue 1, 2011, Pages 28-32

  Seenivasan, A ^a   Panda, Tapobrata ^a   Théodore, Thomas ^b  

^a Department of Chemical Engineering   (India)

^b INDIAN INSTITUTE OF TECHNOLOGY MADRAS   (India)

Author keywords

Lipid emulsions; Lovastatin; Nano structured lipid carriers; Nanoparticles; Solid lipid nanoparticles

Indexed keywords

CARRIER SYSTEMS; CONVENTIONAL DRUGS; DRUG DELIVERY CARRIER; DRUG DELIVERY SYSTEM; HALF LIVES; LATEST TECHNOLOGY; LIPID EMULSIONS; LIPID SYSTEMS; LIPOPHILIC DRUGS; LOVASTATIN; MEDICINAL APPLICATIONS; NANO-STRUCTURED; NANOPARTICLE SYNTHESIS; NANOSTRUCTURED LIPID CARRIERS; RATE-LIMITING STEPS; SITE-SPECIFIC; SOLID LIPID NANOPARTICLES;

BIOCHEMISTRY; NANOPARTICLES; SOLUBILITY;

DRUG DELIVERY;

DRUG CARRIER; MEVINOLIN; NANOPARTICLE; NONSTRUCTURE LIPID NANOPARTICLE; SOLID LIPID NANOPARTICLE; UNCLASSIFIED DRUG;

ARTICLE; DRUG BLOOD LEVEL; DRUG COATING; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG SOLUBILITY; DRUG STABILITY; DRUG SYNTHESIS; DRUG TARGETING; EMULSION; HYDROPHOBICITY; LIPOPHILICITY; NONHUMAN; PARTICLE SIZE; PH; PRIORITY JOURNAL;

EID: 80053618563     PISSN: None     EISSN: 18740707     Source Type: Journal    
DOI: 10.2174/1874070701105010028     Document Type: Article

References (12)

1. Fahr A, Liu X. Drug delivery strategies for poorly water soluble drugs. Expert Opin Drug Deliv 2007; 4(4): 403-16.
2. Blasi P, Giovagnoli S, Schoubben A, Ricci M, Rossi C. Solid lipid nanoparticles for targeted brain drug delivery. Adv Drug Deliv Rev 2007; 59(6): 454-77.
3. Puri A, Loomis K, Smith B, et al. Lipid-based nanoparticles as pharmaceutical drug carriers: from concepts to clinic. Crit Rev Ther Drug Carrier Syst 2009; 26(6): 523-80.
4. Pardeike J, Hommoss A, Müller RH. Lipid nanoparticles (SLN, NLC) in cosmetic and pharmaceutical dermal products. Int J Pharm 2009; 366: 170-84.
5. Kaur IP, Bhandari R, Bhandari S, Kakkar V. Potential of solid lipid nanoparticles in brain targeting. J Control Release 2008; 127(2): 97-109.
6. Chen CC, Tsai TH, Huang ZR, Fang JF. Effects of lipophilic emulsifiers on the oral administration of lovastatin from nanostructured lipid carriers: physicochemical characterization and pharmacokinetics. Eur J Pharm Biopharm 2010; 74: 74-82.
7. Müller RH, Petersen RD, Hommoss A, Pardeike J. Nanostructured lipid carriers (NLC) in cosmetic dermal products. Adv Drug Deliv Rev 2007; 59(6): 522-30.
8. Seenivasan A, Subhagar S, Aravindan R, Viruthagiri T. Microbial production and biomedical applications of lovastatin. Indian J Pharm Sci 2008; 70:701-9.
9. Wissing SA, Kayser OA, Müller RH. Solid lipid nanoparticles for parenteral drug delivery. Adv Drug Deliv Rev 2004; 56(9): 1257-72.
10. Suresh G, Manjunath K, Venkateswarlu V, Satyanarayana V. Preparation, characterization, and in vitro and in vivo evaluation of lovastatin solid lipid nanoparticles. AAPS PharmSciTech 2007; 8(1): E162-70.
11. Radtke M, Souto EB, Müller RH. Nanostructured lipid carriers: a novel generation of solid lipid drug carriers. PharmTech Eur 2005; 17(4): 45-50.
12. Garrett IR, Gutierrez GE, Rossini G, et al. Locally delivered lovastatin nanoparticles enhance fracture healing in rats. J Orthop Res 2007; 25(10): 1351-7.